This article is more than 5 years old. Information may no longer be current.
Four elected to ASH executive committee
Click Here to Manage Email Alerts
Four individuals have been elected to American Society of Hematology’s executive committee.
Their terms will begin after the ASH Annual Meeting and Exposition, scheduled for Dec. 1-4 in San Diego.
Martin S. Tallman, MD, will serve a 1-year term as vice president, followed by successive terms as president-elect and president.
Tallman is chief of the leukemia service at Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College. His research interests include acute myeloid leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia and hairy cell leukemia.
Tallman has been an ASH member for 20 years. He is completing a 3-year term as executive director of Hematology, the society’s education program book. He also helped establish the ASH Meeting on Hematologic Malignancies, serving as its co-chair in 2015 and 2016.
“The most important issue facing hematology today is the remarkably rapid pace of progress in the discovery, dissemination and integration of new knowledge,” Tallman said. “I believe that my past leadership activities in ASH will enable me to effectively contribute to the strategic decision of the executive committee and further ASH’s mission to promote research, clinical care, education, training and advocacy in hematology.”
Mark Crowther, MD, will serve a 4-year term as treasurer.
Crowther is chair of the department of medicine at McMaster University in Canada. His research interests include improving the quality of anticoagulant care through derivation of evidence-based strategies for anticoagulant management and management of complications of anticoagulation, and management of patients with high-risk thrombophilias, focusing on antiphospholipid antibody syndrome.
Belinda R. Avalos, MD, and Arnold Ganser, MD, will serve 4-year terms as councillors.
Avalos is vice chair of the department of hematologic oncology and blood disorders at Levine Cancer Institute at Atrium Health and professor of medicine at The University of North Carolina at Chapel Hill. Her research interests include hematopoiesis and mechanisms of leukemogenesis, congenital neutropenias, receptors and cell signaling, and allogeneic hematopoietic cell transplantation.
Ganser is professor of hematology and oncology and director of the department of hematology, hemostasis, oncology and stem cell transplantation at Hannover Medical School in Germany. His research interests include translational research on hematopoiesis and leukemogenesis, and clinical research on acute myeloid leukemia, myelodysplastic syndrome, bone marrow failure states and stem cell transplantation.
“Drs. Tallman, Crowther, Avalos and Ganser have been dedicated leaders within ASH through their work on various committees. I want to congratulate them on the results of the election, and I look forward to their contributions to the path forward for ASH and its membership,” ASH President Alexis A. Thompson, MD, MPH, professor of pediatrics in the division of hematology, oncology and stem cell transplantation at Northwestern Medicine and associate director of equity and minority health at Ann and Robert H. Lurie Children’s Hospital of Chicago, said in a press release. “Their commitment to leadership will be particularly important for ASH and the field of hematology, which are at the forefront of cutting-edge approaches to treating and curing cancer and other serious blood diseases.”